Exclusive licensing option for solid tumor antibody
Bayer Schering Pharma signs agreement with Micromet
Berlin – Bayer Schering Pharma AG, Germany, has acquired an exclusive option for a collaboration and licensing agreement with Micromet, Inc., a biopharmaceutical company developing antibodies for the treatment of cancer, inflammation and autoimmune diseases. Bayer Schering Pharma will pay Micromet a 4.5 million Euro fee to secure a one-year option on a specific BiTE antibody.
Exercising this option prior to January 5, 2010 through an additional payment would trigger a joint collaboration on the development of the BiTE antibody against a solid tumor target through the completion of Phase I clinical trials, at which point Bayer Schering Pharma would assume full control of the further development and commercialization of the antibody. Micromet would be eligible for an option exercise fee and milestone payments of up to 290 million Euro in total and up to double-digit royalties based on tiered net sales of the product.
“Oncology is one of our core growth areas and biologicals are a key focus of our strategy. We are excited about Micromet’s BiTE antibody technology and believe BiTE antibodies represent a novel and promising approach to cancer therapy,” said Andreas Busch, Member of the Board of Management of Bayer Schering Pharma AG responsible for Global Drug Discovery.
“We are very pleased with Bayer’s interest in this preclinical BiTE antibody program and their financial commitment to secure exclusive access for the next 12 months. This deal represents further validation of BiTE antibody technology by a major oncology company,” said Christian Itin, Micromet’s Chief Executive Officer.
The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subsidiary of Bayer AG, is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Diabetes Care and Pharmaceuticals divisions. The pharmaceuticals business operates under the name Bayer Schering Pharma AG. Bayer HealthCare’s aim is to discover and manufacture products that will improve human and animal health worldwide. Find more information at www.bayerhealthcare.com.
Bayer Schering Pharma is a worldwide leading specialty pharmaceutical company. Its research and business activities are focused on the following areas: Diagnostic Imaging, General Medicine, Specialty Medicine and Women’s Healthcare. With innovative products, Bayer Schering Pharma aims for leading positions in specialized markets worldwide. Using new ideas, Bayer Schering Pharma aims to make a contribution to medical progress and strives to improve the quality of life. Find more information at www.bayerscheringpharma.de.
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.